Imagenebio, Inc. (IMA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Imagenebio, Inc. (formerly Ikena Oncology, Inc.) on August 5, 2025, covering events occurring on August 2, 2025. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol "IMA".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report is strictly limited to a change in the Company's certifying accountant.
Material Changes
- Dismissal of Auditor: On August 2, 2025, the Audit Committee dismissed Ernst & Young LLP ("EY") as the independent registered public accounting firm, effective immediately.
- Engagement of New Auditor: On August 2, 2025, PricewaterhouseCoopers LLP ("PwC") was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Historical Audit Status: EY's audit reports for the years ended December 31, 2024, and 2023 were unqualified and did not contain adverse opinions, disclaimers, or modifications regarding uncertainty, scope, or accounting principles.
- No Disagreements: The Company reported no "disagreements" or "reportable events" with EY during the fiscal years 2023 and 2024 or the interim period through August 2, 2025.
- Prior Relationship: PwC previously served as the auditor for Inmagene Biopharmaceuticals prior to its merger with Imagenebio.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The primary contingency noted is the transition of audit responsibilities from EY to PwC. EY has provided a letter to the SEC (Exhibit 16.1) stating whether they agree with the Company's statements regarding the dismissal.
Investor Verification Checklist
- Review Exhibit 16.1 (Letter from Ernst & Young LLP) to confirm EY's stance on the dismissal and the absence of disagreements.
- Verify the effective date of the new engagement with PwC for the 2025 fiscal year.
- Monitor future filings for the first audit report issued by PwC to ensure continuity in financial reporting standards.
- Check for any subsequent 8-K filings that might disclose the specific rationale for the auditor change, as this filing states the change occurred without reported disagreements.